CONFORMETRIX has signed a two-year collaboration deal with pharma giant AstraZeneca.The spin-out company's proprietary technology will be applied by Astrazeneca across its early-stage drug portfolio to identify which compounds are likely to be successes.Conformetrix’s technology analyses drug molecules to discover how they are likely to react with their targets. The deal with Astrazeneca involves the Anglo-Swiss drugs giant providing an undisclosed upfront payment as well as paying for further research once certain milestones......for the full story register now for free or login below...